Screener
Medpace Holdings, Inc. MEDP Reimbursable Out of Pocket Costs — Total direct costs
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DirectOperatingCosts.
The source filing: Medpace Holdings, Inc.’s 10-Q, filed July 23, 2026.
- Filed
- Jul 23, 2026, 4:03 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001668397-26-000025
| (Amounts in thousands, except per share amounts) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue, net (includes $4.7 million and $16.9 million with related parties for the three months ended June 30, 2026 and 2025, respectively, and $12.0 million and $30.7 million with related parties for the six months ended June 30, 2026 and 2025, respectively) | $707,331 | $603,311 | $1,413,935 | $1,161,881 |
| Operating expenses: | ||||
| Direct service costs, excluding depreciation and amortization | 202,555 | 185,826 | 400,829 | 363,642 |
| Reimbursed out-of-pocket expenses | 303,139 | 237,472 | 615,143 | 439,876 |
| Total direct costs | 505,694 | 423,298 | 1,015,972 | 803,518 |
| Selling, general and administrative | 48,103 | 46,664 | 96,020 | 104,561 |
| Depreciation | 6,555 | 6,777 | 13,306 | 13,471 |
| Amortization | 155 | 237 | 310 | 473 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Medpace Holdings, Inc.'s reimbursable out of pocket costs — total direct costs?
- Medpace Holdings, Inc. (MEDP) reported reimbursable out of pocket costs — total direct costs of $303.14M in Q2 2026.
- How has Medpace Holdings, Inc.'s reimbursable out of pocket costs — total direct costs changed year-over-year?
- Medpace Holdings, Inc.'s reimbursable out of pocket costs — total direct costs increased by 27.7% year-over-year, from $237.47M to $303.14M.
- What is the long-term trend for Medpace Holdings, Inc.'s reimbursable out of pocket costs — total direct costs?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s reimbursable out of pocket costs — total direct costs has grown at a 29.1% compound annual growth rate (CAGR), from $373.13M to $1.04B.
- What does reimbursable out of pocket costs — total direct costs mean?
- This metric represents the total direct operating costs incurred by the company that are contractually billable to clients as reimbursed out-of-pocket expenses. These costs typically include pass-through items such as travel, investigator fees, and laboratory supplies necessary for conducting clinical trials. Tracking these costs is essential for understanding the gross margin impact of pass-through revenue and the efficiency of project-level expense management.
Ask your AI about Medpace Holdings, Inc.'s reimbursable out of pocket costs — total direct costs.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude